Ultragenyx Pharmaceutical

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical is a biopharmaceutical company dedicated to the development of innovative products for the treatment of rare and ultra-rare genetic diseases. Founded in 2010, the company is committed to addressing the unmet medical needs of patients with these conditions through cutting-edge research and development.

With a strong focus on gene therapy and enzyme replacement therapies, Ultragenyx aims to provide transformative treatments that can significantly improve the quality of life for patients. The company’s pipeline includes several promising candidates that are currently in various stages of clinical trials, showcasing its commitment to advancing science and medicine.

Ultragenyx operates with a patient-centric approach, ensuring that the voices of patients and their families are heard throughout the development process. This dedication to patient engagement is reflected in their collaborations with advocacy groups and healthcare professionals.

The company’s headquarters is located in the United States, but it has a growing presence in the UK and other international markets. Ultragenyx is also focused on building a diverse and inclusive workforce, recognising that a variety of perspectives drives innovation.

In addition to its research efforts, Ultragenyx is committed to providing educational resources and support for patients and healthcare providers. The company believes that informed patients are empowered patients, and it strives to facilitate access to information about rare diseases and available treatments.

As Ultragenyx continues to grow, it remains steadfast in its mission to make a meaningful difference in the lives of those affected by rare genetic disorders. Through its innovative therapies and unwavering commitment to patients, Ultragenyx Pharmaceutical is poised to be a leader in the biopharmaceutical industry.